Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
17.98
+0.19 (1.07%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Kevin Danahy |
Contact Details
Address: 3957 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert W. Duggan | Executive Co-Chairman |
| Darrin R. Uecker | Chief Technology Officer, Principal Financial Officer and Director |
| Mitchell E. Levinson | Chief Strategy Officer |
| Kevin P. Danahy | Chief Commercial Officer and Principal Executive Officer |
| Edison Manuel | Vice President of Operations |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
| David Danitz | Senior Vice President of Engineering |
| Dr. Gansevoort Dunnington M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Aug 19, 2024 | 10-Q | Quarterly Report |
| Aug 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 8-K | Current Report |